Publicaciones en las que colabora con Javier Sanz Fuentenebro (10)

2023

  1. Real-life outcomes in biotypes of psychotic disorders based on neurocognitive performance

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 273, Núm. 6, pp. 1379-1386

2022

  1. Relation between EEG resting-state power and modulation of P300 task-related activity in theta band in schizophrenia

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 116

2021

  1. Neurobiological underpinnings of cognitive subtypes in psychoses: A cross-diagnostic cluster analysis

    Schizophrenia Research, Vol. 229, pp. 102-111

2020

  1. Deficits of entropy modulation of the EEG: A biomarker for altered function in schizophrenia and bipolar disorder?

    Journal of Psychiatry and Neuroscience, Vol. 45, Núm. 5, pp. 322-333

2019

  1. Pattern of use of clozapine in Spain. Variability and under-prescription

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 3, pp. 151-162

2014

  1. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia

    Schizophrenia Research, Vol. 158, Núm. 1-3, pp. 223-229

2013

  1. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: Results after one year

    Schizophrenia Research, Vol. 149, Núm. 1-3, pp. 156-161

2012

  1. Clozapine as treatment of first choice in first psychotic episodes. What do we know?

    Actas Espanolas de Psiquiatria, Vol. 40, Núm. 5, pp. 281-289

2008

  1. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia

    International Clinical Psychopharmacology, Vol. 23, Núm. 3, pp. 138-149

2001

  1. Esquizofrenia "resistente". Conceptos confusos y tratamientos esperanzadores

    Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica, Vol. 8, Núm. 1, pp. 11-18